Headline data from the Phase 3 SPRINTER trial did not meet its primary and key secondary endpoints. Whilst obviously disappointing, this can perhaps be explained by the changing way in which hospitalised COVID-19 patients are now treated; the goalposts have moved! Standard of care (SOC), which now includes dexamethasone and remdesivir, has changed since the positive Phase 2 study was conducted. However, the potential for SNG001 to be included in the externally funded platform trials such as RECO ....
21 Feb 2022
Synairgen - Phase 3 headline data readout – missed primary endpoints
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - Phase 3 headline data readout – missed primary endpoints
Synairgen plc (SNG:LON) | 6.7 0 0.0% | Mkt Cap: 13.6m
- Published:
21 Feb 2022 -
Author:
Mark Brewer -
Pages:
11
Headline data from the Phase 3 SPRINTER trial did not meet its primary and key secondary endpoints. Whilst obviously disappointing, this can perhaps be explained by the changing way in which hospitalised COVID-19 patients are now treated; the goalposts have moved! Standard of care (SOC), which now includes dexamethasone and remdesivir, has changed since the positive Phase 2 study was conducted. However, the potential for SNG001 to be included in the externally funded platform trials such as RECO ....